arrow
W

Weifeng Tang

AstraZeneca
H指数:17
被引数:926

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve

基于标准暴露指标和部分曲线下面积评估用于COVID-19预防和治疗的Tixagevimab和Cilgavimab的药代动力学可比性分析

2026-03-310
OAAI
scRNA-Sequencing Reveals Bu-Shen-Yi-Qi Formula (BSYQF) Ameliorates Airway Remodeling via Regulating Imbalanced M1/M2 Macrophage Subtypes in Chronic Asthmatic Mice

单细胞RNA测序揭示补肾益气方(BSYQF)通过调控失衡的M1/M2巨噬细胞亚型改善慢性哮喘小鼠的气道重塑

2025-11-120
PRE
Incorporating maternal metabolome and genome to understand the effects of prenatal phenol exposure on the first 1000-day growth in an exposome-based study

整合母体代谢组与基因组,以理解基于暴露组的研究中产前酚类物质暴露对前1000天生长的影响

2025-09-240
OAAI
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19

在大流行期间加速治疗药物的开发: 长效抗体组合AZD7442 (tixagevimab/cilgavimab) 在预防和治疗新型冠状病毒肺炎中的群体药代动力学

2024-05-023
OAAI